WHO ICTRP trial
Do Serum Alemtuzumab Concentrations Predict Donor T Cell Chimerism after…
NL-OMON51521 · Overview of Medical Research in the Netherlands (NL-OMON) · Recruiting
Key facts
| Trial ID | NL-OMON51521 |
|---|---|
| Public title | Do Serum Alemtuzumab Concentrations Predict Donor T Cell Chimerism after Non-Myeloablative Matched Sibling Donor Stem Cell Transplantation in Sickle Cell Disease Patients? (PREDICT study) |
| Scientific title | Do Serum Alemtuzumab Concentrations Predict Donor T Cell Chimerism after Non-Myeloablative Matched Sibling Donor Stem Cell Transplantation in Sickle Cell Disease Patients? (PREDICT study) - Do Alemtuzumab Levels Predict T cell chimerism after SCT for SCD? |
| Primary sponsor | Hematologie |
| Registry | Overview of Medical Research in the Netherlands (NL-OMON) |
| Recruitment status | Recruiting |
| Study type | Observational invasive |
| Countries | The Netherlands |
| Conditions | hemoglobinopathy Sickle cell disease;10018902;hemoglobinopathy;Sickle cell disease |
| Interventions | ;Alemtuzumab;Chimerism;Sickle cell disease;Stem cell transplantation |
| Registration date | Jul 7, 2022 |
| Target size | 25 |
| Secondary IDs | NL80603.018.22 |
| Registry page | onderzoekmetmensen.nl |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: